Clinical trials and Cancer, the lessons, paradoxes and positives
Investor, Andy Smith, reviews some of the learnings from cancer
clinical trials and examples of what investors have learnt from
compounds in development and a paradox in oncology clinical trials.
Companies mentioned in this talk will include AstraZeneca, OSI
Pharma and Antisoma.
Continuing a series of expert analysis and commentary on the Healthcare sector. Join the discussion and leave your comments and feedback for more on this and other upcoming Global Healthcare sector topics.